CD274 and neoplasm: As to this year, the data reported in ESMO from the ATTRACTION4 (10) and Checkmate 649 (11) have demonstrated encouraging efficacy with Nivolumab combined with SOX/CapeOX, irrespective of tumor PD-L1 expression.